In Brief This Week: Lab21; Vermillion; Thermo Fisher; Ambry, Fluidigm; New England Biolabs; Ezose Sciences, Sigma-Tau | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK-based Lab21 this week said that it has inked an agreement with "one of the world's leading diagnostic businesses" to develop, manufacture, and distribute a molecular diagnostic product for the detection of Aspergillus to run on the partner's real time PCR platform. Neither the name of the partner nor financial details of the agreement were disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.